Chinese biotechnology stocks are emerging as the latest trade related to artificial intelligence, driven by expectations for accelerated drug development and increased returns.
Significant Index Increase
The Hong Kong biotechnology index has increased by nearly 22% this season and is likely to surpass the Hong Kong technology index more than ever since 2015. Investors believe that artificial intelligence can reduce the time and costs of drug research and development. The potential for profitability from AI-generated drugs in the long term could help bolster this trend.
Read more: Final 12-month inflation rate in Spain reached 4.6%
Expected Revenue Growth
Analysts at Citigroup Inc., including John Yang, wrote in a report that the discovery of AI-based drugs in China is progressing due to the speed and cost advantages that AI brings. Given that the penetration of this sector in the $313 billion global pharmaceutical market is still low, it indicates that there is "significant room for growth."
Shares of Insilico Medicine Cayman TopCo have more than doubled since their public offering in Hong Kong at the end of December, while shares of HitGen Inc., listed in Shanghai, have increased by nearly 40% this year. Both companies have received buy ratings from analysts.
Challenges and Opportunities
Unlike many U.S. companies that continue to be unprofitable, several Chinese companies are currently profitable and are expected to see their revenues rise rapidly with increasing demand. Revenue growth related to AI from reputable sellers in the first half of the year and advancements in drug production at companies like Insilico have bolstered positive sentiment in this sector.
Leading Chinese AI drug discovery companies are trading at significant discounts compared to their American counterparts, although ongoing advancements in clinical stages and new collaborations could be catalysts for local companies. Competition remains a concern as contract research organizations, pharmaceutical companies, and private platforms may enter this space.
However, China has a strong combination of scientific talent, a broad pipeline of innovative drugs, and extensive pharmaceutical manufacturing infrastructure for synthesizing and testing AI-generated molecules. Investors should pay attention to proprietary data, domestic advancements in the pipeline, pharmaceutical collaborations, licensing economics, and liquidity status.
Read more: European stock indices decline ahead of Federal Reserve meeting amid escalating tensions in the Gulf · Taiwan stock market closed down 0.73%
